141 related articles for article (PubMed ID: 29567627)
1. Recurrent pseudotumoral relapses in multiple sclerosis: a case report.
Lebrato Hernández L; Díaz Sánchez M; Prieto León M; Cerdá Fuertes NA; Uclés Sánchez AJ; Casado Chocán JL
Mult Scler Relat Disord; 2018 May; 22():49-51. PubMed ID: 29567627
[TBL] [Abstract][Full Text] [Related]
2. Pseudotumoral forms of multiple sclerosis: report of 14 cases and review of the literature.
Mauri-Fábrega L; Díaz-Sánchez M; Casado-Chocán JL; Uclés-Sánchez AJ
Eur Neurol; 2014; 72(1-2):72-8. PubMed ID: 24903642
[TBL] [Abstract][Full Text] [Related]
3. Cortical relapses in multiple sclerosis.
Puthenparampil M; Poggiali D; Causin F; Rolma G; Rinaldi F; Perini P; Gallo P
Mult Scler; 2016 Aug; 22(9):1184-91. PubMed ID: 25791367
[TBL] [Abstract][Full Text] [Related]
4. Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.
Maggi P; Absinta M; Grammatico M; Vuolo L; Emmi G; Carlucci G; Spagni G; Barilaro A; Repice AM; Emmi L; Prisco D; Martinelli V; Scotti R; Sadeghi N; Perrotta G; Sati P; Dachy B; Reich DS; Filippi M; Massacesi L
Ann Neurol; 2018 Feb; 83(2):283-294. PubMed ID: 29328521
[TBL] [Abstract][Full Text] [Related]
5. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse.
Miranda Acuña J; Hidalgo de la Cruz M; Ros AL; Tapia SP; Martínez Ginés ML; de Andrés Frutos CD
Mult Scler Relat Disord; 2017 Nov; 18():157-160. PubMed ID: 29141800
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
[TBL] [Abstract][Full Text] [Related]
9. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
[TBL] [Abstract][Full Text] [Related]
10. Imaging of Central Nervous System Demyelinating Disorders.
Balashov K
Continuum (Minneap Minn); 2016 Oct; 22(5, Neuroimaging):1613-1635. PubMed ID: 27740991
[TBL] [Abstract][Full Text] [Related]
11. Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis.
Zecca C; Disanto G; Sormani MP; Riccitelli GC; Cianfoni A; Del Grande F; Pravatà E; Gobbi C
Mult Scler; 2016 May; 22(6):782-91. PubMed ID: 26459149
[TBL] [Abstract][Full Text] [Related]
12. [Recurrent pseudotumoral multiple sclerosis].
Gonzalez-Delgado M; Tunon A; Guisasola LM; Mateos V
Neurologia; 2004 Mar; 19(2):83-4. PubMed ID: 14986187
[No Abstract] [Full Text] [Related]
13. Relapsing-remitting tumefactive multiple sclerosis.
Selkirk SM; Shi J
Mult Scler; 2005 Dec; 11(6):731-4. PubMed ID: 16320737
[TBL] [Abstract][Full Text] [Related]
14. Polyarteritis nodosa with central nervous system involvement mimicking relapsing-remitting multiple sclerosis.
Ueno K; Matsushima A; Hineno A; Fukushima K; Tazawa K; Matsuda M; Ikeda S
Mod Rheumatol; 2014 May; 24(3):525-8. PubMed ID: 24506572
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
Di Gregorio M; Gaetani L; Eusebi P; Floridi P; Picchioni A; Rosi G; Mancini A; Floridi C; Baschieri F; Gentili L; Sarchielli P; Calabresi P; Di Filippo M
J Neurol; 2018 Mar; 265(3):522-529. PubMed ID: 29327284
[TBL] [Abstract][Full Text] [Related]
17. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Lanzillo R; Quarantelli M; Pozzilli C; Trojano M; Amato MP; Marrosu MG; Francia A; Florio C; Orefice G; Tedeschi G; Bellantonio P; Annunziata P; Grimaldi LM; Comerci M; Brunetti A; Bonavita V; Alfano B; Marini S; Brescia Morra V;
Mult Scler; 2016 Aug; 22(9):1163-73. PubMed ID: 26466947
[TBL] [Abstract][Full Text] [Related]
18. Contralateral recurrence of tumefactive demyelination.
Khan MN; Guranda M; Essig M
Neuroradiol J; 2015 Oct; 28(5):493-7. PubMed ID: 26427896
[TBL] [Abstract][Full Text] [Related]
19. Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study.
Schwartzbach CJ; Grove RA; Brown R; Tompson D; Then Bergh F; Arnold DL
J Neurol; 2017 Feb; 264(2):304-315. PubMed ID: 27888416
[TBL] [Abstract][Full Text] [Related]
20. A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis.
Sethi V; Yousry T; Muhlert N; Tozer DJ; Altmann D; Ron M; Wheeler-Kingshott C; Miller DH; Chard DT
J Neurol Neurosurg Psychiatry; 2016 Jul; 87(7):750-3. PubMed ID: 26272028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
